% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Friedrich:142027,
      author       = {M. Friedrich$^*$ and L. Bunse$^*$ and W. Wick$^*$ and M.
                      Platten$^*$},
      title        = {{P}erspectives of immunotherapy in isocitrate
                      dehydrogenase-mutant gliomas.},
      journal      = {Current opinion in oncology},
      volume       = {30},
      number       = {6},
      issn         = {1040-8746},
      address      = {[S.l.]},
      publisher    = {Ovid},
      reportid     = {DKFZ-2018-02257},
      pages        = {368-374},
      year         = {2018},
      abstract     = {The present review introduces recent progress in eliciting
                      the role of mutant isocitrate dehydrogenase (IDH) in
                      gliomas, especially regarding its mode of action as a
                      modulator of antitumor immune response, and provides
                      rationales for targeting mutant IDH in glioma immunotherapy.
                      Both the development of small molecule inhibitors repressing
                      the enzymatic activity of mutant IDH and novel,
                      mechanism-led combination immunotherapies are
                      discussed.Since the discovery of highly frequent IDH
                      mutations in low-grade gliomas and nonsolid malignancies,
                      its tumor cell-intrinsic effects have been intensively
                      investigated. Tumor cells expressing mutant IDH display
                      profound alterations of redox control capacity, phospholipid
                      profile, and ATP supply. Recent findings suggest that IDH
                      mutations - via intricate, yet druggable pathways - cause
                      immunological alterations, highlighting the importance of
                      oncogenic drivers as modulators of antitumor immunity and
                      targets for immunotherapy.Mutant IDH is not only a
                      disease-defining biomarker and oncogenic driver in glioma,
                      but is also a neoantigen and a regulator of glioma immune
                      evasion. Effective and specific strategies targeting the
                      immunomodulatory properties of mutant IDH may complement
                      current (immuno-)therapeutic strategies and approved
                      antiglioma treatments to improve outcome.},
      subtyp        = {Review Article},
      cin          = {G160 / G370 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)G160-20160331 / I:(DE-He78)G370-20160331 /
                      I:(DE-He78)L101-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30102604},
      doi          = {10.1097/CCO.0000000000000478},
      url          = {https://inrepo02.dkfz.de/record/142027},
}